Reported 23 days ago
BTIG has reduced its price target for Humacyte (HUMA) from $10 to $8 while maintaining a Buy rating, citing an increase in share count as the reason for the adjustment. Despite this, the analyst notes the company’s early commercial success with its Acellular Tissue Engineered Vessel as a positive indicator of its potential impact in the market.
Source: YAHOO